Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
| Image |  |
|---|---|
| Description | scientific article published on 21 March 2011 |
| Author/s |
author: Jose Luis Gonzalez Larriba José Luis Pérez-Gracia Alfonso Calvo Joan Carles Galcerán Enrique Gallardo |
| Publication date | March 21, 2011 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |